208 related articles for article (PubMed ID: 32494207)
1. Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration.
Avaylon J; Lee S; Gallemore RP
Int Med Case Rep J; 2020; 13():145-152. PubMed ID: 32494207
[TBL] [Abstract][Full Text] [Related]
2. [Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].
Book M; Ziegler M; Rothaus K; Faatz H; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
Ophthalmologe; 2022 Mar; 119(3):258-264. PubMed ID: 34351479
[TBL] [Abstract][Full Text] [Related]
3. Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report.
Sim HE; Kim JS; Hwang JH
Case Rep Ophthalmol; 2022; 13(1):166-171. PubMed ID: 35611023
[TBL] [Abstract][Full Text] [Related]
4. The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.
Musiał-Kopiejka M; Polanowska K; Dobrowolski D; Krysik K; Wylęgała E; Grabarek BO; Lyssek-Boroń A
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206485
[TBL] [Abstract][Full Text] [Related]
5. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
7. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
8. Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration.
Ferrone PJ; Anwar F; Naysan J; Chaudhary K; Fastenberg D; Graham K; Deramo V
Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i17-21. PubMed ID: 24795335
[TBL] [Abstract][Full Text] [Related]
9. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
[TBL] [Abstract][Full Text] [Related]
10. A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result.
Kikushima W; Sakurada Y; Fukuda Y; Matsubara M; Kotoda Y; Sugiyama A; Kashiwagi K
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111318
[TBL] [Abstract][Full Text] [Related]
11. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy.
Amaro MH; Roller AB
Arq Bras Oftalmol; 2012; 75(4):273-6. PubMed ID: 23258660
[TBL] [Abstract][Full Text] [Related]
13. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
14. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data.
Agostini H; Mulyukov Z; Tsilimbaris M; Calvo P; Bucher F; Gaucher D; Pigeolet E; Colafrancesco V; Clemens A
Curr Eye Res; 2020 Oct; 45(10):1298-1301. PubMed ID: 32065533
[No Abstract] [Full Text] [Related]
16. Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye.
Maggio E; Alfano A; Mete M; Pertile G
Case Rep Ophthalmol; 2022; 13(3):736-743. PubMed ID: 36845453
[TBL] [Abstract][Full Text] [Related]
17. Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series.
Chakraborty D; Sheth JU; Boral S; Sinha TK
Am J Ophthalmol Case Rep; 2021 Dec; 24():101197. PubMed ID: 34504981
[TBL] [Abstract][Full Text] [Related]
18. Early Predictive Factors of Visual Loss at 1 Year in Neovascular Age-Related Macular Degeneration under Anti-Vascular Endothelial Growth Factor.
Kodjikian L; Rezkallah A; Decullier E; Aulagner G; Huot L; Mathis T;
Ophthalmol Retina; 2022 Feb; 6(2):109-115. PubMed ID: 33991711
[TBL] [Abstract][Full Text] [Related]
19. Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy.
Murray JE; Gold AS; Latiff A; Murray TG
Clin Ophthalmol; 2021; 15():4731-4738. PubMed ID: 34983996
[TBL] [Abstract][Full Text] [Related]
20. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
